Medically Reviewed Content
Written by Rob Anderson, Health Technology Researcher & Medical Content Specialist. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.
Ozempic and Zepbound are two of the most talked-about weight loss medications in 2026, but they work through different mechanisms and carry different FDA approvals. If you are deciding between these options, understanding how they compare on effectiveness, cost, side effects, and accessibility will help you make the right choice for your weight loss goals.
What Is the Difference Between Ozempic and Zepbound?
Ozempic (semaglutide) is a GLP-1 receptor agonist, while Zepbound (tirzepatide) is a dual GIP/GLP-1 receptor agonist. This means Zepbound activates two gut hormone receptors instead of one, which clinical trials suggest produces more significant weight loss in many patients. Ozempic is FDA-approved for type 2 diabetes (with off-label weight loss use), while Zepbound is the weight loss version of Mounjaro. For a broader comparison of these active ingredients, see our semaglutide vs tirzepatide comparison.
Weight Loss Results: Ozempic vs Zepbound
In clinical trials, tirzepatide (Zepbound) generally produced greater average weight loss than semaglutide (Ozempic). The SURMOUNT trials showed average weight loss of 20 to 25 percent of body weight on the highest tirzepatide dose, compared to roughly 15 percent with semaglutide in the STEP trials. However, individual results vary significantly, and both medications produce meaningful weight loss for most patients. Our semaglutide weight loss data guide covers expected results in detail.
Side Effects Comparison
Both Ozempic and Zepbound share common GLP-1 class side effects including nausea, vomiting, diarrhea, and constipation. These are typically most pronounced during the initial titration period and improve over time. Some patients report that tirzepatide has slightly different gastrointestinal effects than semaglutide, though head-to-head comparison data is limited. Check our comprehensive GLP-1 side effects guide for detailed information on managing these effects.
Take the Free Eligibility Quiz →
Cost and Insurance Coverage
Both medications carry similar retail prices in the $1,000+ per month range without insurance. Insurance coverage varies, with Ozempic sometimes having broader coverage due to its longer market presence. Both Novo Nordisk and Eli Lilly offer savings cards for eligible commercially insured patients. Compounded versions of both semaglutide and tirzepatide are available at lower prices through online GLP-1 telehealth programs.
Which Should You Choose?
The best choice depends on your specific health profile, insurance coverage, and weight loss goals. Patients who have tried semaglutide without sufficient results may benefit from switching to tirzepatide’s dual-action mechanism. If cost is a primary concern, compare pricing options for both medications. Discuss with your healthcare provider which medication aligns best with your medical history and treatment goals.
Take the Free Eligibility Quiz →
Sources & References
- U.S. Food and Drug Administration (FDA) – Drug Approvals and Databases
- National Institutes of Health (NIH) – PubMed Medical Literature
- American Diabetes Association – Medication & Therapies
- Novo Nordisk – Clinical Research Data
- Eli Lilly – Medical Information
This content is regularly reviewed and updated to reflect the latest medical research and FDA guidance.